Advertisement

Detection of Cytoplasmic HIV-Encoded Antigens by Flow Cytometry and Monoclonal Anti-HIV-Specific Antibodies Demonstrated in Cultured T-Cells from Certain Hemophilia Patients in Spite of Their Treatment Exclusively with Dry Heat Inactivated Factor VIII Concentrates

  • P. Wernet
  • E. M. Schneider
  • P. Sarin
  • H. H. Brackmann
Conference paper

Zusammenfassung

Patients with hemophilia have been at high risk for HIV infection from contaminated clotting factor concentrates. Although it has thus far not been possible to document HIV in a variety of these concentrates, the general prevalence of HIV antibodies in hemophilic patients is between 50%–70% [1].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Eyster ME, Goedert JJ, Serngadharon MG, Weiss S, Gallo R, Blattner WA (1985) Development and early natural history of HTLV III antibodies in persons with hemophilia. JAMa 253: 2219PubMedCrossRefGoogle Scholar
  2. 2.
    Egli J, Wernet P, Brackmann HH, Kessler M (1984) AIDS in the Federal Republic of Germany. In: Proceedings of the Fourth International Symposium on Hemophilia Treatment. Tokyo, 71Google Scholar
  3. 3.
    Wernet P, Schneider EM, Jaschonek K, Barr-Sinoussi F, Chermann JC, Kessler M, Brackmann HH, Egli H (1986) Assessment of LAV 1 antibodies in hemophilia patients substituted with Detection of Cytoplasmic HIV-Encoded Antigens 151 distinct types of factor VIII: Striking absence of LAV 1 antibodies after exclusive use of heat treated factor VIII concentrates. In: Landbeck G, Marx R (eds) 2. Rundtischgespräch: Therapiebedingte Infektionen und Immundefekte bei Hämophilen. 15. Hämophiliesymposion, Hamburg 1984. Springer-Verlag, Berlin, 104Google Scholar
  4. 4.
    Petriaciani JC, McDougal JS, Evatt B (1985) Case for concluding that heat-treated, licenced anti- haemophilic factor is free from HTLV III. Lancet ii: 890CrossRefGoogle Scholar
  5. 5.
    McDougal JS, Martin LS, Cort SP, Mozen M, Heldebrant CM, Evatt BL (1985) Thermal inactivation of the acquired immunodeficiency Syndrome virus, human T lymphotropic virus-III/ lymphadenopathy-associated virus, with special reference to antihemophilic factor. J Clin Invest 76: 875PubMedCrossRefGoogle Scholar
  6. 6.
    Rouzioux C, Chamaret S, Montagnier L, Carnelli V, Rolland G, Maunucci PM (1985) Absence of antibodies to MDS-virus in haemophiliacs treated with heat-treated factor VIII. The Lancet i: 271CrossRefGoogle Scholar
  7. 7.
    Hollinger FB, Dolana G, Thomas W, Gyokey F (1984) Reduction in risk of hepatitis transmission by heat treatment of human factor VIII concentrate. J Inf Dis 150: 250CrossRefGoogle Scholar
  8. 8.
    Colombo M, Maunucci PM, Carnelli V, Sanidge GF, Garengel C, Schimpf K, and the European Study Group (1985) Transmission of non-A, non-B hepatitis by heat treated factor VIII concentrate. The Lancet ii: 1CrossRefGoogle Scholar
  9. 9.
    Veronese DM, Sarngadharan MG, Rahman R, Markham PD, Popovic M, Bodner AJ, Gallo RC (1985) Monoclonal antibodies specific for p24, the major core protein of human T-cell leukemia virus type III. Proc Natl Acad Sei USA 82: 5199CrossRefGoogle Scholar
  10. 10.
    Wernet P, Göhring S, Sugg U, Schneider EM, Brackmann HH, Egli H, Schneider W (in press) Zum HIV-Problem der Faktor-VHI-substituierten Hämophiliepatienten in diagnostischer und prognostischer Hinsicht. In: Stangel W, Kretschmer V (Hrsg) Aktuelle Probleme der Trans-fusionsmedizin. Z f InfusionstherapieGoogle Scholar
  11. 11.
    Schneider EM, Wernet P, Ostendorf P, Barre-Sinoussi F, Chermann JC, Kessler M, Brackmann HH, Egli H (1986) Surface marker data and functional analysis of hemophilia patients with and without antibodies to LAV1. In: Landbeck G, Marx R (eds) 2. Rundtischgespräch: Therapiebedingte Infektionen und Immundefekte bei Hämophilen. Springer-Verlag, p 91Google Scholar
  12. 12.
    Schneider EM, Pawelec G, Liangru S, Bühring HJ, Wernet P (in press) Generation of CD4- positive suppressor T cells from mixed lymphocyte cultures in the presene of Interleukin-2 reeeptor antibody TÜ69: An in vitro model for transplantationGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • P. Wernet
    • 1
    • 2
    • 3
  • E. M. Schneider
    • 1
    • 2
    • 3
  • P. Sarin
    • 1
    • 2
    • 3
  • H. H. Brackmann
    • 1
    • 2
    • 3
  1. 1.TübingenGermany
  2. 2.BethesdaUSA
  3. 3.BonnGermany

Personalised recommendations